Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Eli Lilly & Co. LLY, +0.53% gained 0.8% in premarket trading on Tuesday after the company told investors as part of its third-quarter earnings that it has started the process to seek approval from the Food and Drug Administration for its experimental Alzheimer's drug, donanemab. It also said it plans to conduct a Phase 3 clinical trial evaluating donanemab against Aduhelm, Biogen Inc.'s BIIB, +1.94% recently approved Alzheimer's drug, to assess "superiority of brain amyloid plaque clearance in early symptomatic Alzheimer's disease.

Lilly plans to run clinical trial comparing its Alzheimer's drug candidate to Biogen's Aduhelm

Eli Lilly (NYSE:LLY) reported its Q3 earnings results on Tuesday, October 26, 2021 at 06:25 AM. Here's what investors need to know about the announcement.

Eli Lilly: Q3 Earnings Insights

Eli Lilly & Co. LLY, +0.53% said Tuesday its third-quarter net income fell 8% to $1.11 billion, or $1.22 a share, from $1.21 billion, or $1.33 a share in the year-ago period. Adjusted net income increased to $1.94 a share from $1.41 a share.

Eli Lilly & Co. net income falls 8%, but adjusted profit rises

Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, mainly due to higher sales of its COVID-19 antibody therapies, and the drugmaker said it has initiated a rolling submission for its experimental Alzheimer's treatment.

Lilly raises 2021 outlook on higher COVID-19 drugs sales

INDIANAPOLIS, Oct. 26, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced financial results for the third quarter of 2021 today. "Lilly demonstrated strong performance again this quarter.

Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential

Align Technology

Haemonetics

Moderna

Phreesia Inc

Vertex Pharmaceuticals

Management's Discussion of Fund Performance1

Eaton Vance Worldwide Health Sciences Fund 2021 Annual Report

Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.

Could This Be the Next Blockbuster Indication for Eli Lilly?

Johnson & Johnson

AbbVie

Amgen

Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio breadth, its earnings often serve as a bellwether for the sector, according to BofA Securities analyst Geoff Meacham.

3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat

INDIANAPOLIS, Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine in detailed results from Eli Lilly and Company's (NYSE: LLY) SURPASS-4 clinical trial, which were published today in The Lancet . At 52 weeks, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (-25.8 lb.

Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk

INDIANAPOLIS, Oct. 18, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock. The dividend is payable on December 10, 2021 to shareholders of record at the close of business on November 15, 2021.

Lilly Declares Fourth-Quarter 2021 Dividend

INDIANAPOLIS, Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC). These data were presented at today's ESMO Virtual Plenary and simultaneously published in the Annals of Oncology.

Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology

INDIANAPOLIS, Oct. 13, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), in combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score of ≥20% as determined by an FDA-approved test. Ki-67 is a marker of cellular proliferation.

FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer

INDIANAPOLIS, Oct. 12, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2021 financial results on Tuesday, October 26, 2021. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement

Bank of Montreal

Exxon Mobil

Eli Lilly, Exxon Mobil, and Bank of Montreal are among the most stable income stocks you can find.

3 Top Stocks That Have Been Paying Dividends for a Combined 467 Years

INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021. The data will be presented as part of the plenary session titled "New Drugs on the Horizon II" as well as in individual poster presentations.

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

AstraZeneca

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Pfizer

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

After a hot start to 2021, the drugmaker's share price has cooled off over the last month.

Eli Lilly Stock: Buy on the Dip?

A recently recalled batch of Glucagon Emergency Kits, Eli Lilly and Co's therapy for diabetic patients in crisis, was manufactured at an Indiana factory cited by U.S. health regulators this year for quality-control violations, including several involving that product, according to the company and a Reuters review of federal inspection records.

Exclusive: Eli Lilly's recalled emergency diabetes drug came from plant cited by FDA

The stock price of ​Eli Lilly has seen a decline of 11% over the last twenty-one trading days. There are a couple of factors that fueled this decline.

Will Eli Lilly Stock Rebound After An 11% Fall Last Month?

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2021 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the launch of CRMSynced™, an educational initiative that uses gamification to encourage healthcare professionals (HCPs) to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) conditions.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients. Related:   Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year.

Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients

INDIANAPOLIS, Oct. 1, 2021 /PRNewswire/ -- Patients taking mirikizumab for their moderately to severely active ulcerative colitis (UC), were in symptomatic remission for up to two years as demonstrated in new results from Eli Lilly and Company's (NYSE: LLY) Phase 2 study. Symptomatic remission is defined as no more than two bowel movements more than an individual's normal bowel frequency, and no blood in their stool.

At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study

Eli Lilly And Co (NYSE: LLY) posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose monitoring (CGM) for 7 to 10 days at baseline. Related Link:   Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study.

News for Eli Lilly Stock (LLY)